

# Colorectal Cancer Pathways

Patient Name: \_\_\_\_\_

Date of Birth: \_\_\_\_\_

Member Number: \_\_\_\_\_

Treatment Start Date: \_\_\_\_\_

**Pathology:** \_\_\_\_\_

**Stage:** \_\_\_\_\_

**Line of Therapy:** \_\_ Adjuvant/Post-Op \_\_ 1<sup>st</sup> Line \_\_ 2<sup>nd</sup> Line  
\_\_ 3<sup>rd</sup> Line \_\_ 3<sup>rd</sup> Line+

**ECOG Performance Status:** \_\_\_\_\_ **ICD-10 Code:** \_\_\_\_\_

**Biomarkers/Characteristics:** (select all that apply)

RAS: \_\_ Wild type \_\_ Mutant

## Adjuvant Therapy\*

Capecitabine (Xeloda)

**FOLFOX:** fluorouracil (5-FU), leucovorin, and oxaliplatin

**FULV:** fluorouracil (5FU) and leucovorin

## Metastatic Disease | RAS Wild Type (WT) or Mutant (MT)<sup>†</sup> | First or Second Lines of Therapy (1<sup>st</sup> or 2<sup>nd</sup> Line)

Capecitabine (Xeloda)

**FOLFIRI:** fluorouracil (5FU), leucovorin, and irinotecan (Camptosar)

**FOLFIRI + bevacizumab:** fluorouracil (5FU), leucovorin, and irinotecan (Camptosar) with bevacizumab (Avastin)

**FOLFOX:** fluorouracil (5FU), leucovorin, and oxaliplatin

**FOLFOX + bevacizumab:** fluorouracil (5FU), leucovorin, oxaliplatin, with bevacizumab (Avastin)

**FOLFOXIRI + bevacizumab:** fluorouracil (5FU), leucovorin, oxaliplatin, and irinotecan (Camptosar) with bevacizumab (Avastin)

**FULV:** fluorouracil (5FU) and leucovorin

**FULV:** fluorouracil (5FU) and leucovorin with bevacizumab (Avastin)

## Metastatic Disease | RAS Wild Type (WT) | First or Second Lines of Therapy (1<sup>st</sup> or 2<sup>nd</sup> Line)

**FOLFIRI + panitumumab:** fluorouracil (5FU), leucovorin, and irinotecan (Camptosar) with panitumumab (Vectibix)<sup>‡</sup>

**FOLFOX + panitumumab:** fluorouracil (5-FU), leucovorin, and oxaliplatin with panitumumab (Vectibix)<sup>‡</sup>

Irinotecan (Camptosar) and panitumumab (Vectibix)<sup>‡</sup>

## Metastatic Disease | MSI-H or dMMR | Second Line of Therapy (2<sup>nd</sup> Line)

Pembrolizumab (Keytruda)

## Metastatic Disease | RAS Wild Type (WT) | Third or Subsequent Lines of Therapy (3<sup>rd</sup> Line+)

Panitumumab (Vectibix) monotherapy<sup>‡</sup>

\*Adjuvant Pathways do not apply to stage II MSI-H (microsatellite instability-high) disease

<sup>†</sup>Exon 2 KRAS, non-exon 2 KRAS, and NRAS mutations; testing recommended for all patients with metastatic disease

<sup>‡</sup>Limit to one line of therapy

**Note:** Pathways are independent of specific health plan medical policy coverage criteria. Health plan medical policy/clinical guidelines should be consulted to determine whether proposed services will be covered.